scholarly journals Serum Complement C3 and C4 Levels in Relation to Diagnosis of Lupus Nephritis

2008 ◽  
Vol 7 (4) ◽  
pp. 1117 ◽  
Author(s):  
N Hussain ◽  
G Jaffery ◽  
S Hasnain
Keyword(s):  
Lupus Nephritis ◽  
Complement C3 ◽  
Serum Complement

scholarly journals Serum complement levels as prognostic marker for monitoring treatment response in lupus nephritis

2021 ◽  
Vol 11 (2) ◽  
pp. 97-102
Author(s):  
Saiful Bahar Khan ◽  
Rafi Nazrul Islam ◽  
Md Saif Bin Mizan ◽  
AKM Shahidur Rahman ◽  
Shah Md Zakir Hossain ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Disease Activity ◽  
Treatment Response ◽  
Lupus Erythematosus ◽  
Treatment Initiation ◽  
Complement C3 ◽  
P Value ◽  
Serum Complement ◽  
Systemic Lupus

Background: Lupus nephritis (LN) is one of the most common and serious manifestations of systemic lupus erythematosus (SLE) that causes significant morbidity and mortality. Certain biomarkers for LN are sometimes able to assess treatment response in lupus nephritis. This study aimed to compare serum complement levels (C3 and C4) as markers of treatment response of LN and their relation to the LN class in renal biopsy. Methods: This prospective observational study was conducted in the Department of Nephrology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from July 2018 to August 2019. Twenty seven patients who were diagnosed with LN after kidney biopsy were included in this study. Serum complement levels (C3 and C4), 24 hours urinary total protein (24-hr UTP) and anti-double-stranded DNA (anti-ds DNA) were measured in all patients at baseline, 3 months and 6 months after treatment initiation. These biomarker values before and after treatment were compared between the proliferative and non-proliferative LN patients. Results: Serum C3 levels were significantly different between patients with proliferative LN (Class III and Class IV) and non-proliferative LN (Class V) at baseline (0.47 ± 0.32 g/l versus 0.89 ± 0.43 g/l, p=0.009) and levels changed significantly 6 months after treatment initiation (p<0.001) and likewise for serum C4 levels (0.10 ± 0.06 g/l versus 0.24 ± 0.26 g/l, p=0.040). The values of 24-hr UTP and anti-ds-DNA were significantly different 6 months after treatment with p value <0.05 in both groups but C3 (p<0.001) and renal Systemic Lupus Erythematosus Disease Activity Index (rSLEDAI) (p<0.001) were only significant in the proliferative group. On the other hand, after 6 months treatment, C4 levels became relatively higher but that was not significant in both groups (p>0.05). Conclusion: After 6 months of treatment, serum C3 and C4 levels increased towards normal in both LN groups. Serum C3 and C4 levels in patients with LN correlate with disease activity. Therefore, serum complement (C3 and C4) levels may be utilized as serological biomarkers for treatment response of LN. Birdem Med J 2021; 11(2): 97-102

scholarly journals MiR-384 is associated with renal damage in lupus nephritis via regulation of TET3 expression

2021 ◽  
Vol 19 (12) ◽  
pp. 2571-2576
Author(s):  
Jun Zhang ◽  
Suli Lu ◽  
Ting Ding ◽  
Haijia Zhao ◽  
Dongxing Tang
Keyword(s):  
Lupus Nephritis ◽  
Serum Creatinine ◽  
Renal Damage ◽  
Complement C3 ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Complement ◽  
Urine Protein ◽  
Qrt Pcr ◽  
Potential Biomarker ◽  
Protein Serum

Purpose: To investigate the correlations between miR-384 expression and renal damage in lupus nephritis (LN).Methods: Lupus nephritis and normal tissues were collected during surgery. The relative miR-384 expression was evaluated by extracting RNA and performing quantitative real time PCR (qRT-PCR) assays. Expression of ten-eleven translocation (TET3) mRNA and protein were measured by qRT-PCR and western blotting, respectively. The 24-h urine protein, serum complement C3, and serum creatinine were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits. TargetScan and luciferase assays were used to validate the binding site for miR-384 and its target mRNA. Relationships among miR-384, TET3, and renal damage were analyzed by Spearman rank-order correlation coefficients.Results: MiR-384 expression increased in LN tissues and was positively correlated with the activity index (AI) and chronicity index of LN, whereas miR-384 expression and serum complement C3 were negatively correlated. Positive correlations were observed between miR-384 expression and 24-h urine protein, serum creatinine, and systemic lupus erythematosus disease AI. TargetScan and luciferaseassays indicated that the TET3 3′-UTR was the direct target of miR-384. MiR-384 upregulation inhibited TET3 mRNA and protein  expression, and was negatively associated with renal damage in LN.Conclusion: MiR-384 upregulation contributes to renal damage in LN by targeting the 3′-UTR of TET3 mRNA, suggesting that miR-384 is a potential biomarker and therapeutic target in LN. Keywords: MiR-384, Renal damage, Lupus nephritis, Ten-eleven translocation, TET3

Serum Complement C3 and Type 2 Diabetes in Rheumatoid Arthritis: A Case-Control Study

2018 ◽  
Vol 13 (3) ◽  
pp. 215-221 ◽  
Author(s):  
Francesco Ursini ◽  
Salvatore D`Angelo ◽  
Emilio Russo ◽  
Giorgio Ammerata ◽  
Ludovico Abenavoli ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Type 2 Diabetes ◽  
Case Control Study ◽  
Case Control ◽  
Complement C3 ◽  
Serum Complement ◽  
Control Study

scholarly journals Lupus Nephritis: Role of Serum Complement Levels as Prognostic Marker

2020 ◽  
Vol 6 (1) ◽  
pp. 01-05
Author(s):  
Richmond Gomes
Keyword(s):  
Lupus Nephritis ◽  
Treatment Response ◽  
Lupus Erythematosus ◽  
Serum Complement ◽  
Class Iii ◽  
Proliferative Lupus Nephritis ◽  
Significant Difference ◽  
Before And After ◽  
Assess Treatment Response ◽  
Serological Biomarkers

Background: Lupus Nephritis (LN) is one of the most common and serious manifestations in Systemic Lupus Erythematosus (SLE) patients that causes significant morbidity and mortality. Certain biomarkers for LN are sometimes able to assess treatment response of lupus nephritis. Objective: To compare serum complement levels (C3 & C4) as markers of treatment response of LN and their relation to the LN class in renal biopsy. Methods: This prospective observational study was conducted in the Department of Nephrology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from July 2018 to August 2019. Twenty seven patients who were diagnosed with lupus nephritis after kidney biopsy were included in this study. Serum complement levels (C3 & C4), 24 hours urinary total protein (24-hr UTP) and anti-double-stranded DNA (anti-ds DNA) were measured in all patients at baseline, 3 months and 6 months after treatment. These biomarker values before and after treatment were compared between the treatment response and non response groups. Results: Serum C3 levels were significantly different in patients of proliferative lupus nephritis (Class III & Class IV) than non proliferative lupus nephritis (Class V) at baseline (0.47 ± 0.32 vs0.89 ± 0.43g/l, p = 0.009) and levels changed significantly 6 months after treatment (p <0.001) and likewise for Serum C4 levels (0.10 ± 0.06 vs0.24 ± 0.26g/l, p = 0.040). Serum C3 levels were also found to correlate significantly with SLEDAI and renal SLEDAI. No significant difference was observed for 24-hr UTP levels at baseline between remission and non-remission groups. Conclusion: Serum C3 & C4 levels may be utilized as serological biomarkers to predict and monitor the treatment response of lupus nephritis.

Early-stage predictors for treatment responses in patients with active lupus nephritis

Lupus ◽  
2019 ◽  
Vol 28 (3) ◽  
pp. 283-289 ◽  
Author(s):  
G Liu ◽  
H Wang ◽  
J Le ◽  
L Lan ◽  
Y Xu ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Serum Albumin ◽  
Immunosuppressive Therapy ◽  
Early Stage ◽  
Complement C3 ◽  
Class Iii ◽  
Class V ◽  
Predictive Values ◽  
Cutoff Value ◽  
Active Lupus Nephritis

Objective We analyzed data of lupus nephritis (LN) patients to find parameters that can predict remission. Methods Sixty-four LN patients who were diagnosed with class III, IV, V or V + III/IV by renal biopsy and were followed up for more than six months in our center were enrolled retrospectively. Receiver operating characteristic curves were used to test the predictive values of urinary protein-to-creatinine ratio (UPCR), serum albumin and complement C3 at the first, second and third months as predictors for remission at the sixth month. Results The patients' renal pathologies were class III (five cases), class IV (33 cases), class V (nine cases) and class V + III/IV (17 cases). All patients received standard immunosuppressive therapy. Forty-six (71.9%) patients (grouped as the remission group) achieved remission at the end of the sixth month, including 23 complete remissions and 23 partial remissions. The other 18 patients were grouped as the no-remission group. There were no significant differences in clinical data, proportion of immunosuppressive therapy or renal pathological characteristics between the remission group and no-remission group at baseline, except the serum urea nitrogen of the remission group was lower than in the no-remission group. The UPCR were significantly lower in the remission group than in the no-remission group at months 1, 2, 3 and 6, respectively, while the serum albumin was significantly higher in the remission group than in the no-remission group at months 3 and 6, respectively. There were no significant differences in serum creatinine between the remission group and no-remission group, except at month 1. The C3 levels were higher in the remission group than in the no-remission group at months 1, 2 and 3, respectively. The areas under the curve (AUC) of the change percentage of UPCR at month 3 and the serum albumin at month 3 were the most significant (AUC 0.778, p = 0.002; AUC 0.773, p = 0.001, respectively). The cutoff value of the change percentage of UPCR at month 3 was 59%. The cutoff value of serum albumin at month 3 was 32.9g/l. Conclusion The change percentage of UPCR ≥59% and the serum albumin ≥32.9 g/l at the third month were valuable for predicting remission at the sixth month in LN. Because of the small-size and retrospective nature, this study needs to be validated.

Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis

Lupus ◽  
2020 ◽  
Vol 29 (4) ◽  
pp. 371-378
Author(s):  
J M Mejia-Vilet ◽  
Y J López-Hernández ◽  
J I Santander-Vélez ◽  
M Trujeque-Matos ◽  
C Cruz ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Lupus Nephritis ◽  
Receptor Agonist ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Response To Therapy ◽  
Complement C3 ◽  
Microvascular Damage ◽  
Media Thickness ◽  
Medial Hyperplasia

Angiotensin II type 1 receptor agonist antibodies (AT1R-AAs) have been associated with hypertension, atherosclerosis and vascular inflammation in human diseases. The aim of the study was to evaluate the prevalence of AT1R-AAs in active lupus nephritis (LN) patients and their association with vascular damage. One hundred and seven active LN patients underwent a complete clinical examination, measurement of AT1R-AAs, ambulatory blood pressure monitoring, carotid intima-media thickness measurement and morphometric analysis of subintimal fibrosis and medial hyperplasia of the vessels in the kidney tissue. Plasma AT1R-AAs were positive in 58 (54.2%) patients. The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, complement C3 and C4 levels and titers of anti-dsDNA antibodies were higher in the group with positive AT1R-AAs compared with those with negative AT1R-AAs. The AT1R-AA titers correlated with anti-dsDNA antibody titers and with complement C3 and C4 serum levels. In the kidney biopsy, the percentage of subintimal fibrosis and the area of medial hyperplasia were greater in the AT1R-AA-positive patients. No differences in arterial pressure, carotid intima-media thickness and response to therapy were detected. In conclusion, AT1R-AAs are prevalent in active LN patients and are associated with histologic features of microvascular damage.

scholarly journals Serum complement (C3, C4) levels in patients with acute myocardial infarction and angina pectoris

2008 ◽  
Vol 33 (3) ◽  
pp. 98-102 ◽  
Author(s):  
ASM Giasuddin ◽  
Jamila M ElMahdawi ◽  
Fakhri M ElHassadi
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Angina Pectoris ◽  
Acute Phase ◽  
Significant Positive Correlation ◽  
Complement C3 ◽  
Serum Complement ◽  
Positive Correlation ◽  
Control Subjects

Serum complement (C3, C4) levels in Libyan patients with acute myocardial infarction (AMI; 31 patients) and angina pectoris (AP; 11 patients) at the 1st day and 7th day of attack were estimated. A group of 26 healthy Libyans were taken as control subjects (CS). Serum C3 and C4 levels (mean ± SD, mg/dl) were elevated at the 1st day in AMI as well as AP patients (C3 → AMI1: 154.0 ± 28.5, AP1: 152.0 ± 45.0, CS: 132.0 ± 8.0, ANOVA: p=0.0072; C4→ AMI1: 38 ± 13, AP1: 37 ± 17, CS: 29 ± 6, ANOVA: p=0.0160). No significant differences for the elevated C3 and C4 levels at the 1st day were observed between the two diseases groups (AMI1 vs AP1 → C3: p=0.879, C4: p=0.818). At the 7th day, C3 and C4 levels were further elevated in AMI, while they remained at the similar elevated levels in AP (C3 → AMI 7: 173.1 ± 28.0, AP 7: 149.0 ± 41.0, CS: 132.0 ± 8.0, ANOVA: p=0.0000; C4 → AMI 7: 46.0 ± 7.0, AP 7: 36.0 ± 15.0, CS: 29.0 ± 6.0, ANOVA: p=0.0000). Again, no significance differences for the raised C3 and C4 levels at the 7th day was observed between AMI and AP patients (AMI 7 vs AP 7 → C3: P=0.059, C4: p=0.06). The C3 elevation showed significant positive correlation in AMI group (r=0.522, p=0.003) while it was insignificant in AP patients (r=0.037, p=0.915). Regarding C4 levels, it was significantly correlated in AMI (r=0.483, p=0.006), and in AP, although it was positively correlated (r=0.656, P=0.028) the observed difference was not significant (t=0.29, p=0.778). In conclusion, serum C3 and C4 levels were more profoundly elevated in AMI compared to AP patients suggestive of an acute phase and inflammatory response.DOI = 10.3329/bmrcb.v33i3.1141Bangladesh Med Res Counc Bull 2007; 33: 98-102

Sign in / Sign up

Export Citation Format

Share Document